Even though the Oncology Care Model (OCM) ended on June 30, 2022, there are some improvements that practices should continue implementing, said Susan Escudier, MD, FACP, vice president of value-based care and quality programs, Texas Oncology.
Even though the Oncology Care Model (OCM) ended on June 30, 2022, there are some improvements that practices should continue implementing, said Susan Escudier, MD, FACP, vice president of value-based care and quality programs, Texas Oncology.
Note: This interview took place prior to the June 30, 2022, end of the OCM.
Transcript
What do you hope or expect practices will continue to do even after the OCM ends?
I think the things, to me, that were important: I like our standardized treatment plans. I find them to be a nice teaching tool for the patient to explain their diagnosis, their prognosis. I hand it to them. I hand them a drug handout. They go home, they share it with their family. It's a nice way for them to be able to go home and study the information and think about it. Also, sometimes they forget what we tell them, so it’s helpful for that aspect.
I think the patient outreach—like calling patients after treatments—I think that should stick around. I think one of our big wins was being able to cut the turnaround time on getting patient calls answered. I think that's a big win we need to keep.
I think there are a lot of improvements that were made—our depression screenings, our distress screenings increased—and those are things we really need to keep doing going forward.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Orca-T showed lower rates of graft-vs-host disease or infection compared with allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome (MDS) or acute leukemias in the Precision-T trial, Caspian Oliai, MD, MS, UCLA Bone Marrow Transplantation Stem Cell Processing Center, said.
Read More